Patents by Inventor Kyung Eun Park

Kyung Eun Park has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11993702
    Abstract: The present disclosure provides a thermoplastic resin composition having high rigidity and a low coefficient of linear thermal expansion and a molded article including the same. Specifically, the thermoplastic resin composition includes a base resin including at least two polypropylene-based resins having different melt indexes, an elastomer having a melt index (190° C., 2.16 kg) of 20 g/10 min to 35 g/10 min as measured by ASTM D1238, and inorganic particles, and has a flexural modulus (FM) of 2,500 MPa or more and a coefficient of linear thermal expansion (CLTE) of 60 ?m/m° C. or less.
    Type: Grant
    Filed: July 6, 2022
    Date of Patent: May 28, 2024
    Assignees: HYUNDAI MOTOR COMPANY, KIA CORPORATION, LOTTE CHEMICAL CORPORATION
    Inventors: Jin Young Yoon, Hee Joon Lee, Dong Eun Cha, Sun Jun Kwon, Chun Ho Park, Seung Ryong Jeong, Kyung Hwan Lim, Eun Hwa Jang
  • Patent number: 11978382
    Abstract: An input sensing device includes sensor pixels initialized in response to a reset signal provided through a reset line, and output a sensing signal to a read-out line in response to a scan signal provided through a scan line. A controller generates at least one start signal and clock signals. A selector selectively provides the at least one start signal and the clock signals to first control lines or second control lines. A reset driver connected to the first control lines, and supplying reset signals to at least some of the reset lines based on the at least one start signal and the clock signals provided through the first control lines. A scan driver is connected to the second control lines, and supplies scan signals to at least some of the scan lines based on the at least one start signal and the clock signals.
    Type: Grant
    Filed: December 12, 2022
    Date of Patent: May 7, 2024
    Assignee: Samsung Display Co., Ltd.
    Inventors: Kyung Tea Park, Jong Hyun Lee, Kang Bin Jo, Go Eun Cha
  • Patent number: 11975076
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.
    Type: Grant
    Filed: November 12, 2021
    Date of Patent: May 7, 2024
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Publication number: 20240097799
    Abstract: Disclosed is an amplification circuit, which includes a first amplifier that receives an external signal and performs first band pass filtering on the external signal to output a first filter signal, and a second amplifier that receives the first filter signal and performs second band pass filtering on the first filter signal to output a second filter signal, and a frequency pass bandwidth of the second band pass filtering is narrower than a frequency pass bandwidth of the first band pass filtering.
    Type: Application
    Filed: June 26, 2023
    Publication date: March 21, 2024
    Applicant: Electronics and Telecommunications Research Institute
    Inventors: Sung Eun KIM, Tae Wook KANG, Hyuk KIM, Kyung Hwan PARK, Mi Jeong PARK, Hyung-IL PARK, Kyung Jin BYUN, Kwang IL OH, Jae-Jin LEE, In Gi LIM
  • Patent number: 11932618
    Abstract: Disclosed are novel compounds of Chemical Formula 1, optical isomers of the compounds, and pharmaceutically acceptable salts of the compounds or the optical isomers. The compounds, isomers, and salts exhibit excellent activity as GLP-1 receptor agonists. In particular, they, as GLP-1 receptor agonists, exhibit excellent glucose tolerance, thus having a great potential to be used as therapeutic agents for metabolic diseases. Moreover, they exhibit excellent pharmacological safety for cardiovascular systems.
    Type: Grant
    Filed: March 13, 2023
    Date of Patent: March 19, 2024
    Assignee: ILDONG PHARMACEUTICAL CO., LTD.
    Inventors: Hong Chul Yoon, Kyung Mi An, Myong Jae Lee, Jin Hee Lee, Jeong-geun Kim, A-rang Im, Woo Jin Jeon, Jin Ah Jeong, Jaeho Heo, Changhee Hong, Kyeojin Kim, Jung-Eun Park, Te-ik Sohn, Changmok Oh, Da Hae Hong, Sung Wook Kwon, Jung Ho Kim, Jae Eui Shin, Yeongran Yoo, Min Whan Chang, Eun Hye Jang, In-gyu Je, Ji Hye Choi, Gunhee Kim, Yearin Jun
  • Publication number: 20240078836
    Abstract: An input sensing device includes: sensor pixels, a horizontal driver, a selection circuit, and a vertical driver. Each of the sensor pixels is connected to a plurality of driving lines and a one of a plurality of signal input lines. The horizontal driver sequentially applies a horizontal driving signal to the sensor pixels through the driving lines. The selection circuit is connected to n of the signal input lines (n is a natural number of 2 or more) and to one output line. The selection circuit sequentially outputs n sensing signals received through the n signal input lines to the one output line. The vertical driver receives the n sensing signals through the one output line. The horizontal driver applies the horizontal driving signal n times to a given one of the driving lines to correspond to the n sensing signals.
    Type: Application
    Filed: November 8, 2023
    Publication date: March 7, 2024
    Inventors: Kyung Tea PARK, Jong Hyun LEE, Kang Bin JO, Go Eun CHA
  • Publication number: 20240078835
    Abstract: An input sensing device includes: sensor pixels, a horizontal driver, a selection circuit, and a vertical driver. Each of the sensor pixels is connected to a plurality of driving lines and a one of a plurality of signal input lines. The horizontal driver sequentially applies a horizontal driving signal to the sensor pixels through the driving lines. The selection circuit is connected to n of the signal input lines (n is a natural number of 2 or more) and to one output line. The selection circuit sequentially outputs n sensing signals received through the n signal input lines to the one output line. The vertical driver receives the n sensing signals through the one output line. The horizontal driver applies the horizontal driving signal n times to a given one of the driving lines to correspond to the n sensing signals.
    Type: Application
    Filed: November 8, 2023
    Publication date: March 7, 2024
    Inventors: Kyung Tea PARK, Jong Hyun LEE, Kang Bin JO, Go Eun CHA
  • Patent number: 11923882
    Abstract: A hybrid communication device, an operation method thereof, and a communication system including the same are provided. The hybrid communication device includes a contact unit that includes an antenna for receiving a first communication signal and an electrode for receiving a second signal, a switch controller that includes a first switch and a second switch and controls the first switch and the second switch based on a change in capacitance of the electrode, and a signal processing unit that receives at least one of the first communication signal and the second communication signal from the contact unit via the first switch and processes the received signal. The first switch is connected to the contact unit, and the signal processing unit is connected to the first switch.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: March 5, 2024
    Assignee: Electronics and Telecommunications Research Institute
    Inventors: Tae Wook Kang, Sung Eun Kim, Hyung-Il Park, Jae-Jin Lee, Hyuk Kim, Kyung Hwan Park, Mi Jeong Park, Kyung Jin Byun, Kwang Il Oh, In Gi Lim
  • Publication number: 20230405139
    Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: June 13, 2023
    Publication date: December 21, 2023
    Inventors: Yun-Hee Park, Ho Young Song, Hyun Min Ryu, Sung Min Kim, Ju Yuel Baek, Ji Hye Oh, Nara Han, Hyoung Rae Kim, Kyung Eun Park, Hyeun Joung Lee, Ju Young Lee, Dae Hyuck Kang, Young-Jae Yang, Ji-na You, Yong Zu Kim, Chang Sun Lee, Jeiwook Chae, Jinwon Jung, Juhee Kim, Bora Lee, Daehae Song, Byungje Sung, Donghoon Yeom, Jaehyun Eom, Youngeun Hong, Jinhyung Ahn, Yangsoon Lee, Kyungjin Park, Jiseon Yoo, Minji Park
  • Publication number: 20230310640
    Abstract: The present invention relates to a pyrrolobenzodiazepine derivative compound, a conjugate of the same with a ligand, and the use of the same. The pyrrolobenzodiazepine derivative compound is more stable in plasma, is stable even in circulation, and exhibits excellent efficacy. In particular, the conjugate of the pyrrolobenzodiazepine derivative compound with a ligand has a great advantage in that it is possible to target and specifically treat proliferative disease such as cancer, maximize drug efficacy, and minimize the expression of side effects since the conjugate more stably reaches the target cell and effectively exerts drug efficacy while toxicity is greatly reduced as a linker technology that allows drugs to be easily released within cancer cells and maximize drug efficacy is incorporated.
    Type: Application
    Filed: December 30, 2020
    Publication date: October 5, 2023
    Inventors: Ho Young SONG, Yun-Hee PARK, Kun Jung LEE, Ji Hye OH, Sung Min KIM, Kyung Eun PARK, Yong Gyu PARK, Hyun Min RYU, Na Ra HAN, Chul Woong CHUNG, Jei Wook CHAE, Yong Zu KIM
  • Publication number: 20230270868
    Abstract: The present invention relates to a pyrrolobenzodiazepine dimer prodrug and a ligand-linker conjugate compound thereof, a composition containing these, and therapeutic use thereof particularly as an anticancer drug. The stability of the compounds themselves and the stability thereof in plasma are excellent and the compounds are advantageous in terms of manifestation of toxicity, and thus the compounds are industrially useful in that it is possible to target proliferative diseases such as cancer, to perform a specific treatment, to maximize the drug efficacy, and to minimize the occurrence of side effects.
    Type: Application
    Filed: February 24, 2023
    Publication date: August 31, 2023
    Inventors: Ho Young Song, Sung Min Kim, Hyoungrae Kim, Kyung Eun Park, Chul-Woong Chung, Yun-Hee Park, Hyo Jung Choi, Su In Lee, Juyuel Baek, Hyeun Joung Lee, Ju Young Lee, Ji Hye Oh, Jeiwook Chae, Yeong Soo Oh, Yong Zu Kim
  • Patent number: 11707533
    Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.
    Type: Grant
    Filed: July 27, 2020
    Date of Patent: July 25, 2023
    Assignees: LegoChem Biosciences, Inc., ABL Bio, Inc.
    Inventors: Yun-Hee Park, Ho Young Song, Hyun Min Ryu, Sung Min Kim, Ju Yuel Baek, Ji Hye Oh, Nara Han, Hyoung Rae Kim, Kyung Eun Park, Hyeun Joung Lee, Ju Young Lee, Dae Hyuck Kang, Young-Jae Yang, Ji-Na You, Yong Zu Kim, Chang Sun Lee, Jeiwook Chae, Jinwon Jung, Juhee Kim, Bora Lee, Daehae Song, Byungje Sung, Donghoon Yeom, Jaehyun Eom, Youngeun Hong, Jinhyung Ahn, Yangsoon Lee, Kyungjin Park, Jiseon Yoo, Minji Park
  • Patent number: 11654197
    Abstract: The present disclosure relates to pyrrolobenzodiazepine dimer prodrugs and ligand-linker conjugates thereof. The present disclosure also relates to compositions and uses of said prodrugs and conjugates.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: May 23, 2023
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Ho Young Song, Sung Min Kim, Hyoungrae Kim, Kyung Eun Park, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Su In Lee, Juyuel Baek, Hyeun Joung Lee, Ju Young Lee, Ji Hye Oh, Jeiwook Chae, Yeong Soo Oh, Yong Zu Kim
  • Patent number: 11413353
    Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and an active agent. The antibody-drug conjugate may comprise a self-immolative group. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: August 16, 2022
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Publication number: 20220226496
    Abstract: The present invention relates to a ligand-drug conjugate including a ligand; a linker that is connected to the ligand by a covalent bond and has a tris structure represented by a specific structural formula; and an active agent connected to the linker by a covalent bond. In the ligand-drug conjugate, the active agent is bound by the tris structure of the linker, and thus a greater number of active agents can be connected through one linker. Accordingly, a greater number of active agents per antibody binding can be delivered to the target cell, and the drug and/or toxin can stably reach the target cell and effectively exert the drug efficacy.
    Type: Application
    Filed: April 29, 2020
    Publication date: July 21, 2022
    Inventors: Ho Young SONG, Yun-Hee PARK, Sang Eun CHAE, Ju Yuel BAEK, Kyung Eun PARK, Ju Young LEE, Su In LEE, Jeiwook CHAE, Chang Sun LEE, Yong Zu KIM
  • Publication number: 20220218840
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.
    Type: Application
    Filed: November 12, 2021
    Publication date: July 14, 2022
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Publication number: 20220218830
    Abstract: The present disclosure relates to pyrrolobenzodiazepine dimer prodrugs and ligand-linker conjugates thereof. The present disclosure also relates to compositions and uses of said prodrugs and conjugates.
    Type: Application
    Filed: March 29, 2018
    Publication date: July 14, 2022
    Inventors: Ho Young Song, Sung Min Kim, Hyoungrae Kim, Kyung Eun Park, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Su In Lee, Juyuel Baek, Hyeun J. Lee, Ju Y. Lee, Ji Hye Oh, Jeiwook Chae, Yeong Soo Oh, Yong Zu Kim
  • Patent number: 11173214
    Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a plurality of active agents are conjugated to an antibody through at least one branched linker. The branched linker may comprise a branching unit, and two active agents are coupled to the branching unit through a secondary linker and the branching unit is coupled to the antibody by a primary linker. The active agents may be the same or different. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g., 2-4 branched linkers, which may each be coupled to a different C-terminal cysteine of a heavy or light chain of the antibody. The branched linker may comprise one active agent coupled to the branching unit by a first branch and a second branch that comprises a polyethylene glycol moiety coupled to the branching unit. In certain such embodiments, two or more such branched linkers are conjugated to the antibody, e.g.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: November 16, 2021
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Patent number: 11167040
    Abstract: In some aspects, the invention relates to an antibody-drug conjugate, comprising an antibody; a linker; and at least two active agents. In preferred embodiments, the linker comprises a peptide sequence of a plurality of amino acids, and at least two of the active agents are covalently coupled to side chains of the amino acids. The antibody-drug conjugate may comprise a self-immolative group, preferably two-self-immolative groups. The linker may comprise an O-substituted oxime, e.g., wherein the oxygen atom of the oxime is substituted with a group that covalently links the oxime to the active agent; and the carbon atom of the oxime is substituted with a group that covalently links the oxime to the antibody.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: November 9, 2021
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Yong Zu Kim, Yeong Soo Oh, Jeiwook Chae, Ho Young Song, Chul-Woong Chung, Yun Hee Park, Hyo Jung Choi, Kyung Eun Park, Hyoungrae Kim, Jinyeong Kim, Ji Young Min, Sung Min Kim, Byung Soo Lee, Dong Hyun Woo, Ji Eun Jung, Su In Lee
  • Publication number: 20210069342
    Abstract: The present invention relates to new antibody-drug conjugates (ADCs) targeting ROR1, active metabolites of such ADCs, methods for preparation of such ADCs, uses for such ADCs in treatment and/or prevention of illnesses, and uses for such ADCs in production of drugs for treatment and/or prevention of diseases, more specifically diseases associated with over-expression of ROR1, for example cancer. More specifically, the present invention relates to an antibody-drug conjugate comprising an antibody that binds to ROR1 or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same.
    Type: Application
    Filed: July 27, 2020
    Publication date: March 11, 2021
    Inventors: Yun Hee Park, Ho Young Song, Hyun Min Ryu, Sung Min Kim, Ju Yuel Baek, Ji Hye Oh, Nara Han, Hyoung Rae Kim, Kyung Eun Park, Hyeun Joung Lee, Ju Young Lee, Dae Hyuck Kang, Young-Jae Yang, Ji-Na You, Yong Zu Kim, Chang Sun Lee, Jeiwook Chae, Jinwon Jung, Juhee Kim, Bora Lee, Daehae Song, Byungje Sung, Donghoon Yeom, Jaehyun Eom, Youngeun Hong, Jinhyung Ahn, Yangsoon Lee, Kyungjin Park, Jiseon Yoo, Minji Park